Articles

SR Pharma has launched a Phase I clinical trial of RTP-801i.

A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) has found it to be both safe and efficacious.

The 1st of March was declared "ORBIS Day" in New York City, USA, by Mayor Michael R. Bloomberg.

Eyemaginations has been selected by Carl Zeiss Meditec to release two new patient education animations.

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss.

Fear of going blind may be more likely to motivate teenagers to stop smoking than the fear of heart or lung disease.

For most patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD), triple therapy offers significant and sustained visual improvement after just one cycle of treatment.

Senior doctors have accused the independent sector treatment centre (ISTC) scheme for NHS cataract services of being an expensive over-reaction to the need to increase the rate of cataract surgery in the UK.

Glaucoma medication timolol exerts a direct antioxidant effect, protecting human endothelial cells from oxidative stress.

The annual cumulative cell loss in eyes implanted with toric iris-fixated phakic intraocular lenses (IOLs) is two to three times greater than in normal eyes without surgery.

IntraLase has entered into an agreement with Escalon Medical to settle all outstanding disputes and litigation between the parties.

GDx variable cornea compensation with scanning laser polarimetry (SLP-VCC), Heidelberg retina tomography (HRT) confocal scanning laser ophthalmoscopy (CSLO) and stereoscopic optic nerve head (ONH) photographs may all be useful in assisting clinicians to diagnose glaucoma.

Trabeculectomy is in danger of becoming a technique performed only by sub-specialists with glaucoma fellowship training unless it becomes a mandatory feature in training programmes.

Phaco-trabeculotomy in addition to deep sclerectomy can offer significant reductions in intraocular pressure (IOP).

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance.

Manual small incision cataract surgery (MSCIS) with trypan blue staining of the anterior capsule is a safe and effective method of cataract extraction for patients with phacolytic glaucoma.

Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).

The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.

Carl Zeiss Meditec has received FDA clearance to market the laser keratome applications of it's Visumax femtosecond laser system.

Why is it that education & training are sometimes regarded as a chore and an unnecessary obligation?

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification.

Lumenis has appointed Dov Ofer as its new designated Chief Executive Officer.

Outlined of a four-point scale that may help to simplify the assessment of a patient's risk of developing age-related macular degeneration (AMD).

The Centers for Medicare and Medicaid Services (CMS) has issued a ruling that will allow Medicare beneficiaries undergoing cataract surgery to choose an astigmatism-correcting intraocular lens (IOL).

Intraocular pressure (IOP) measurements with the Pascal dynamic contour tonometer (PDCT) are relatively immune to changes in corneal biomechanics and pachymetry, according to a study published in the January issue of the American Journal of Ophthalmology.

The US Navy is proceeding with a programme allowing LASIK with IntraLase flap creation in naval aviators.

A new class of lipids, that makes up part of the tear film, has been identified, which could lead to insights into the role of fatty acid amide activity in the human biological system.

Retina specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).

Bausch & Lomb has made an equity investment in AcuFocus.